Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

l in patients with solid tumors; - continuing an investigator-sponsored Phase 1 clinical trial evaluating OGX-427 treatment in patients with bladder cancer; - continuing critical path initiatives including manufacturing and clinical trial readiness activities in anticipation of OGX-011 Phase 3 clinical trials; and - meeting working capital needs, capital expenditures and general corporate purposes.

"We have continued to make solid progress in advancing our product pipeline, most recently with the receipt of Fast Track Designation from the U.S. Food & Drug Administration (FDA) for OGX-011 in combination with first-line docetaxel treatment and the initiation of a Phase 1 clinical trial evaluating OGX-427 in patients with bladder cancer," said Scott Cormack, President and CEO of OncoGenex. "We were also able to complete a $9.5 million registered direct offering that, in addition to strengthening our balance sheet and extending our runway, has given us leverage in our effort to secure a development and commercialization partnership for our OGX-011 program and enabled us to commence critical path initiatives including manufacturing and clinical trial readiness activities in anticipation of OGX-011 Phase 3 clinical trials."

"The partnering discussions continue to advance," Cormack added. "In addition to evaluating economic terms, we have been focusing on the level of commitment by potential partners to a development plan for OGX-011. As we are presently drafting definitive agreements, we believe that we are on track to secure a development and commercialization partnership for OGX-011."

It has been widely reported that the Galleon Group is in the process of liquidating all of its funds and winding down its operations. The Galleon Group has verbally confirmed to OncoGenex management that it completed the liquidation of its entire position in OncoGenex on October 20, 2009.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014   MSC , a healthcare ... today announced the appointment of Mary Beth Loesch ... 28 years of experience preparing companies for rapid growth ... Executive Vice President of Corporate Development and Healthcare. In ... business , as well as corporate strategy and marketing. ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316662/Global-Chelating-Agents-Market-2014-2018.html About Chelating Agent ... can form covalent bonds with metal ions, thereby ... effect that some metal-ions have on chemical processes, ...
(Date:8/27/2014)... 27, 2014  A novel biomarker for rheumatoid ... better identify early-stage disease, when treatment can often ... a new study in The Journal of Rheumatology. ... DGX ) and other institutions found that ... conventional antibody-serum testing, including rheumatoid factor (RF) and ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a new ... - A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds ... microelectronics to water treatment, but is graphene the ... the Graphene Opportunity Report, authored by Tim ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... PAC more accurately tracks true drug acquisition cost , ... announced today an agreement with Glass Box Analytics ... Predictive Acquisition Cost (PAC). Glass Box Analytics developed ... that more closely tracks true drug acquisition cost. PAC employs ...
...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a ... as XIAFLEX® in the U.S. and XIAPEX® in Europe ... will present at the following upcoming investor conferences during ... Cowen and Company 32nd Annual Health Care Conference ...
... of light as short as a few femtoseconds from the ... University of East Anglia (UEA) measure how energy is transferred ... structures for exploiting solar radiation. , Funded by a ... the new laser will be used for 2D electronic spectroscopy ...
Cached Biology Technology:Elsevier/Gold Standard Exclusive Publisher of New Predictive Drug Price Type 2Elsevier/Gold Standard Exclusive Publisher of New Predictive Drug Price Type 3BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March 2New laser can point the way to new energy harvesting 2
(Date:8/27/2014)... to listen carefully to someone, the first thing we ... is stop moving altogether. This strategy helps us hear ... movements. , This interplay between movement and hearing also ... evidence has long suggested that the brain,s motor cortex, ... gives rise to our conscious perception of sound. , ...
(Date:8/27/2014)... giant, frightening beasts. But every creature is a baby ... containing fossils of 24 very young dinosaurs and one ... overseen by a caretaker, according to a new study ... Hedrick and Peter Dodson led the work, collaborating with ... the specimen is held. Hedrick is a doctoral student ...
(Date:8/27/2014)... into doubt the long-standing belief that a deficiency in ... plays a central role in depression. In the journal ... lacking the ability to make serotonin in their brains ... did not show depression-like symptoms. , Donald Kuhn ... Center and Wayne State University School of Medicine note ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... areas of the United States, reversing 100 years of ... Wildlife Management , raises new conservation questions, such as ... "The cougar population declined dramatically from 1900, due to ... remaining population isolated to the American west," said Michelle ...
... , During heavy rain, the lid of Nepenthes ... that seek shelter on its underside directly into the ... published today, Wednesday 13 June, in the journal ... insects as a source of nutrients, enabling them to ...
... vertebrates on Earth resembled a shark, according to a new ... has long puzzled paleontologists. New research on Acanthodes ... on the evolution of the earliest jawed vertebrates and offers ... split between the earliest sharks and the first bony fishes ...
Cached Biology News:Cougars are re-populating their historical range, new study confirms 2Pitcher plant uses rain drops to capture prey 2Where we split from sharks: Common ancestor comes into focus 2Where we split from sharks: Common ancestor comes into focus 3
... Jouan RC Standard MB (For small quantities ... biology samples) of vacuum concentrator/centrifugal evaporator systems ... and biochemistry for rapid and safe concentration ... be expanded with pumps, different of cold ...
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
For testing the AQUA technique on your MS instruments....
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: